A detailed history of Price T Rowe Associates Inc transactions in Tenaya Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 3,513,724 shares of TNYA stock, worth $7.84 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,513,724
Previous 3,346,522 5.0%
Holding current value
$7.84 Million
Previous $17.5 Million 37.76%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$2.72 - $4.99 $454,789 - $834,337
167,202 Added 5.0%
3,513,724 $10.9 Million
Q1 2024

May 15, 2024

SELL
$2.88 - $6.8 $3.45 Million - $8.15 Million
-1,198,021 Reduced 26.36%
3,346,522 $17.5 Million
Q4 2023

Feb 14, 2024

BUY
$1.73 - $3.39 $120,022 - $235,188
69,377 Added 1.55%
4,544,543 $14.7 Million
Q3 2023

Nov 14, 2023

BUY
$2.55 - $5.65 $14,088 - $31,216
5,525 Added 0.12%
4,475,166 $11.4 Million
Q2 2023

Aug 14, 2023

BUY
$2.64 - $7.64 $218,745 - $633,035
82,858 Added 1.89%
4,469,641 $26.2 Million
Q1 2023

May 15, 2023

SELL
$1.92 - $3.59 $164,004 - $306,654
-85,419 Reduced 1.91%
4,386,783 $12.5 Million
Q4 2022

Feb 14, 2023

BUY
$1.68 - $3.19 $3.96 Million - $7.52 Million
2,357,950 Added 111.53%
4,472,202 $8.99 Million
Q3 2022

Nov 14, 2022

SELL
$2.9 - $5.88 $3.63 Million - $7.36 Million
-1,252,528 Reduced 37.2%
2,114,252 $6.13 Million
Q2 2022

Aug 15, 2022

BUY
$5.01 - $14.12 $1.68 Million - $4.74 Million
335,378 Added 11.06%
3,366,780 $19 Million
Q1 2022

May 16, 2022

BUY
$9.41 - $19.3 $356,629 - $731,450
37,899 Added 1.27%
3,031,402 $35.7 Million
Q4 2021

Feb 14, 2022

BUY
$18.41 - $29.58 $4.06 Million - $6.52 Million
220,394 Added 7.95%
2,993,503 $55.6 Million
Q3 2021

Nov 15, 2021

BUY
$15.35 - $26.66 $42.6 Million - $73.9 Million
2,773,109 New
2,773,109 $56 Million

Others Institutions Holding TNYA

About Tenaya Therapeutics, Inc.


  • Ticker TNYA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,364,700
  • Market Cap $92.2M
  • Description
  • Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hyp...
More about TNYA
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.